New Jersey Senate Bill SR27

New Jersey 2022-2023 Regular Session

• Introduced: 1/18/22
• Refer: 1/18/22

Caption

Urges Biden Administration to lift regulatory freeze on executive orders designed to reduce cost of life-saving prescription drugs for Americans.

Impact

The proposed resolution calls attention to the significant burden high medication prices place on vulnerable populations including seniors, low-income individuals, and the uninsured. By lifting the regulatory freeze, the resolution argues that Americans would be able to access life-saving drugs at more manageable costs. This could lead to a strategic shift in how medications are priced and distributed within the healthcare system, ultimately intended to benefit consumers who are currently suffering from exorbitant pharmacy fees.

Summary

Senate Resolution No. 27, introduced in New Jersey, urges the Biden Administration to lift a regulatory freeze on executive orders that aim to reduce the cost of life-saving prescription drugs for Americans. The resolution highlights the executive orders issued by former President Donald Trump on July 24, 2020, which sought to lower prices for medications, notably insulin and epinephrine, and proposed measures such as passing savings from manufacturers directly to patients at community health centers. The intent is to enhance affordability for millions of Americans in need of these essential medications.

Contention

There are notable points of contention surrounding the executive orders mentioned in the resolution. Proponents, including Senator Joseph Pennacchio, argue that the orders would eliminate the hidden costs inflicted by middlemen in the pharmaceutical supply chain and thereby improve access to necessary medications. Critics, however, argue that such measures may not fully address the complexities of medication pricing and distribution, and that simply lifting the freeze without a comprehensive approach may not solve the fundamental challenges that lead to high drug costs for consumers.